Globe Axial Length Growth at Age 10.5 Years in the Infant Aphakia Treatment Study.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
08 2020
Historique:
received: 07 11 2019
revised: 06 04 2020
accepted: 07 04 2020
pubmed: 19 4 2020
medline: 3 10 2020
entrez: 19 4 2020
Statut: ppublish

Résumé

To report the change in globe axial length (AL) from the time of unilateral cataract surgery at age 1-7 months to age 10.5 years for infants enrolled in the Infant Aphakia Treatment Study, and to compare AL growth of operated eyes with that of fellow unoperated eyes. Comparative case series. AL growth was analyzed relative to treated vs fellow eye, contact lens (CL) vs intraocular lens (IOL), visual acuity (VA) outcome, and the need for surgery for visual axis opacification. Eyes with glaucoma or glaucoma suspect were excluded from the primary analysis but reported separately. Fifty-seven patients have reliable AL data available at both visits. AL was shorter in treated eyes preoperatively (P < .0001) and at 10.5 years of age (P = .021) but AL growth was not different (4.7 mm, P = .99). The growth (70.2% up to age 5 and 29.8% from age 5 to 10.5) was similar in the CL and the IOL group (P = .79). Eyes grew 4.4 mm when visual acuity (VA) was better than 20/200, and 5.2 mm when VA was 20/200 or worse (P = .076). Eyes receiving additional surgery grew more than eyes not receiving additional surgery (P = .052). Patients with glaucoma showed significantly more eye growth (7.3 mm) than those without glaucoma (4.7 mm) and glaucoma suspects (5.1 mm) (P < .05). Eyes with glaucoma or poor VA often grew longer than the fellow eye. Overall, treated eyes grew similarly in the IOL and CL groups and also kept pace with the growth of the fellow eyes.

Identifiants

pubmed: 32304705
pii: S0002-9394(20)30178-1
doi: 10.1016/j.ajo.2020.04.010
pmc: PMC7593806
mid: NIHMS1585358
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

147-155

Subventions

Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY013272
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY013287
Pays : United States
Organisme : NEI NIH HHS
ID : UG1 EY025553
Pays : United States
Organisme : NEI NIH HHS
ID : UG1 EY013272
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

J Cataract Refract Surg. 1999 Sep;25(9):1209-13
pubmed: 10476503
Dev Ophthalmol. 2016;57:29-39
pubmed: 27043390
Arch Ophthalmol. 2010 Jan;128(1):21-7
pubmed: 20065212
Ophthalmology. 2017 May;124(5):730-733
pubmed: 28196730
Br J Ophthalmol. 1999 Mar;83(3):265-9
pubmed: 10365030
Acta Ophthalmol Scand. 1996 Jun;74(3):220-3
pubmed: 8828714
J Cataract Refract Surg. 2009 Jul;35(7):1223-8
pubmed: 19545812
J AAPOS. 2004 Feb;8(1):50-5
pubmed: 14970800
Am J Ophthalmol. 2004 Dec;138(6):915-24
pubmed: 15629281
Ophthalmic Surg. 1993 Jul;24(7):467-75
pubmed: 8351094
J AAPOS. 2006 Oct;10(5):460-3
pubmed: 17070483
Invest Ophthalmol Vis Sci. 2012 Nov 07;53(12):7539-45
pubmed: 23074203
J AAPOS. 2016 Jun;20(3):210-3
pubmed: 27109053
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4671-8
pubmed: 17898291

Auteurs

M Edward Wilson (ME)

Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA. Electronic address: wilsonme@musc.edu.

Rupal H Trivedi (RH)

Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA.

David R Weakley (DR)

Department of Ophthalmology, Southwestern University, Dallas, Texas, USA.

George A Cotsonis (GA)

Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Scott R Lambert (SR)

Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH